LUNG CANCER

In the second installment of this series, Edward B. Garon, MD, MS, explains the rationale for using combination IO therapies alongside chemotherapy for first-line treatment of metastatic non-small cell lung cancer (NSCLC), discusses key data from the POSEIDON trial presented at recent meetings, and elaborates on how these regimens may change his clinical practice.

Data from the phase 3 PEARL study show that durvalumab does not induce statistically significant overall survival in patients with metastatic non–small cell lung cancer.

Closing out his discussion on the management of advanced non–small cell lung cancer, an expert oncologist provides his hopes for future evolutions in the treatment paradigm.

In light of clinical data and real-world experience, Jason Porter, MD, considers how he would best select patients with non–small cell lung cancer for IO therapy.

Jason Porter, MD, shares a brief review of the toxicity profile noted on EMPOWER-Lung3 and provides practical advice on how to monitor for and manage adverse events.

Expert perspective on the EMPOWER-Lung3 clinical trial, which combined cemiplimab with chemotherapy as frontline treatment for patients with advanced NSCLC.

Comprehensive insight on the first-line treatment armamentarium available to patients diagnosed with metastatic squamous cell non–small cell lung cancer.

Centering discussion on a patient scenario of metastatic squamous cell NSCLC, expert oncologist Jason Porter, MD, shares his initial impressions on the case.

During a Targeted Oncology case-based roundtable event, Patrick Forde, MBBCh, discussed the use of the regimen consisting of nivolumab, ipilimumab, and 2 cycles of chemotherapy for non–small cell lung cancer.

Findings from 3 studies show that treatment with plinabulin elicits efficacy and reduces the duration of severe neutropenia in patients with non–small cell lung cancer receiving docetaxel.

A safety review committee has approved the Acclaim-1 trial of ozeplasmid plus osimertinib in non–small cell lung cancer to move on to the third cohort of the study.

Dr Joel Neal reviews data from the pivotal clinical trial leading to the FDA approval of mobocertinib for EGFR exon 20-mutated advanced or metastatic lung cancers.

Dr Luis Raez shares his perspectives on ways to manage thrombocytopenia in patients receiving chemotherapy for ES-SCLC treatment.

Dr Piotrowska highlights the currently approved targeted therapies for EGFR exon 20 mutation-positive mNSCLC.

During a Targeted Oncology case-based roundtable event, Rafael Santana-Davila, MD, discussed with participants which patients are candidates for chemoimmunotherapy for advanced non–small cell lung cancer. This is the second of 2 articles based on this event.

During a Targeted Oncology case-based roundtable event, Benjamin Levy, MD, discussed the current targeted treatment options that target lung cancers that are positive for ALK rearrangements.

Frontline treatment with dostarlimab and chemotherapy reduced the risk of disease progression and led to better objective response rates and progression-free survival vs pembrolizumab in patients with metastatic non-squamous non–small cell lung cancer.

Nurse Practitioner Lauren Welch and Dr Michelle Shiller explain if and when they would offer repeat liquid or tissue biopsies to a patient with mNSCLC, and discuss how often patients request “serial biopsies” for detecting treatment response and/or disease progression.

A key opinion leader muses on the treatments she would consider for a patient with mNSCLC, an EGFR exon 20 mutation, and brain metastases.

Shirish M. Gadgeel, MD, MBBS, discusses the results of the KRYSTAL-1 trial trial of adagrasib in patients with KRAS-positive non–small cell lung cancer.

Joshua Sabari, MD, a thoracic medical oncologist at NYU Langone Health Perlmutter Cancer Center in New York, NY reviews clinical trial data and explains the rationale of using tumor-infiltrating lymphocytes (TILs) in non-small cell lung cancer (NSCLC) treatment.

An interim overall survival analysis of the novel therapy sitravatinib combined with nivolumab has cleared the way for a continuation of the phase 3 SAPPHIRE study in patients with advanced non-squamous non–small cell lung cancer.

During a Targeted Oncology case-based roundtable event, Gregory Riely, MD, PhD, discussed with participants the adverse event management and expected efficacy of mobocertinib for patients with non–small cell lung cancer and an EGFR exon 20 insertion. This is the second of 2 articles based on this event.

Edward B. Garon, MD, MS, provides an overview of the phase 3 CANOPY-A study.

The panel reviews the first- and second-line treatment options for the patient in the presented case, before and after knowing her molecular testing results.